Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related …
K Brinkman, JA Smeitink, JA Romijn, P Reiss - The Lancet, 1999 - thelancet.com
K Brinkman, JA Smeitink, JA Romijn, P Reiss
The Lancet, 1999•thelancet.comHighly active antiretroviral therapy (HAART) can induce a characteristic lipodystrophy
syndrome of peripheral fat wasting and central adiposity. HIV-1 protease inhibitors are
generally believed to be the causal agents, although the syndrome has also been observed
with protease-inhibitor-sparing regimens. Here, we postulate that the mitochondrial toxicity
of the nucleoside-analogue reverse-transcriptase inhibitors plays an essential part in the
development of this lipodystrophy, similar to the role of mitochondrial defects in the …
syndrome of peripheral fat wasting and central adiposity. HIV-1 protease inhibitors are
generally believed to be the causal agents, although the syndrome has also been observed
with protease-inhibitor-sparing regimens. Here, we postulate that the mitochondrial toxicity
of the nucleoside-analogue reverse-transcriptase inhibitors plays an essential part in the
development of this lipodystrophy, similar to the role of mitochondrial defects in the …
Summary
Highly active antiretroviral therapy (HAART) can induce a characteristic lipodystrophy syndrome of peripheral fat wasting and central adiposity. HIV-1 protease inhibitors are generally believed to be the causal agents, although the syndrome has also been observed with protease-inhibitor-sparing regimens. Here, we postulate that the mitochondrial toxicity of the nucleoside-analogue reverse-transcriptase inhibitors plays an essential part in the development of this lipodystrophy, similar to the role of mitochondrial defects in the development of multiple symmetrical lipomatosis.
thelancet.com